InNexus Biotechnology Announces a Significant Expansion to its Intellectual Property and Product Development Strategy TSX.V: IXS OTC BB: IXSBF VANCOUVER, June 2 /PRNewswire-FirstCall/ -- InNexus Biotechnology, Inc. is pleased to announce an expansion to its Intellectual Property portfolio. InNexus has filed additional claims and support for its SuperAntibodies(TM), capable of creating high therapeutic potency through binding and cross-linking of target antigens. InNexus has been issued patents and has other applications pending and in review for worldwide protection on its method for creating SuperAntibodies(TM). The current filing is an expansion of claims for specific SuperAntibody products, primarily derived from existing FDA-approved monoclonal antibodies. SuperAntibody Technology can be used to create second-generation, improved versions of marketed antibodies thereby expanding market indications, revenues and prolonging the patent life. The patent filing allows InNexus to work with companies desiring to bring next generation products to market or companies wanting to develop competitive products to those already on the market. To support this business strategy, InNexus has produced SuperAntibody versions of existing, FDA-approved monoclonal antibody products, demonstrated their therapeutic superiority to the marketed products and used the information to file specific product and indication claims. With this information and specific patent claims, InNexus believes it can expand its financial support and develop further collaborations for product development. Dr. Charles Morgan, President & CEO of InNexus stated, "This is an important, value-adding component to SuperAntibody Technology because it allows faster entry into the marketplace with SuperAntibodies into proven high value markets; for which revenues can be projected with reasonable confidence". About InNexus InNexus is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMAbs(TM), which improve the potency of existing antibody products while opening new markets and disease applications. Both platforms utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia, Canada and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus please visit http://www.innexusbiotech.com/. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities. On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President & CEO Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. DATASOURCE: InNexus Biotechnology, Inc. CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788,

Copyright